Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Nektar Therapeutics News

Aktie
WKN:  A419UB ISIN:  US6402683063 US-Symbol:  NKTR Branche:  Biotechnologie Land:  USA
71,70 €
+0,70 €
+0,99%
20:47:20 Uhr
Depot/Watchlist
Marktkapitalisierung *
7,03 Mrd. €
Streubesitz
27,94%
KGV
-5,04
Index-Zuordnung
-

Nektar Therapeutics News

02.07.25 - PR Newswire
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
01.07.25 - PR Newswire
Nektar Therapeutics Announces Pricing of $100 Million Public Offering
Nektar Therapeutics Announces Pricing of $100 Million Public Offering PR Newswire
30.06.25 - PR Newswire
Nektar Therapeutics Announces Proposed Public Offering
Nektar Therapeutics Announces Proposed Public Offering PR Newswire
24.06.25 - PR Newswire
REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis
REZOLVE-​AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-​to-Severe Atopic Dermatitis PR Newswire
23.06.25 - PR Newswire
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-​AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on ...
13.05.25 - PR Newswire
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference PR Newswire
08.05.25 - PR Newswire
Nektar Therapeutics Reports First Quarter 2025 Financial Results
Nektar Therapeutics Reports First Quarter 2025 Financial Results PR Newswire
01.05.25 - PR Newswire
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets PR Newswire

Newssuche

Videos

newspaper
16.04.26 +3,07%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »